Cargando…
Determinants of the Cancer Drug Funding Process in Canada
Background: Canada has a publicly funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) (now renamed the CADTH reimbursement review) makes a non-binding funding recommendation to the Canadian provinc...
Autores principales: | Gotfrit, Joanna, Jackson, Ashley, Shin, John J. W., Stewart, David J., Mallick, Ranjeeta, Wheatley-Price, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946987/ https://www.ncbi.nlm.nih.gov/pubmed/35323362 http://dx.doi.org/10.3390/curroncol29030162 |
Ejemplares similares
-
The Pathway for New Cancer Drug Access in Canada
por: Gotfrit, Joanna, et al.
Publicado: (2022) -
Access to Cancer Drugs in Canada
por: Wheatley-Price, Paul
Publicado: (2022) -
Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models
por: Glennie, Judith, et al.
Publicado: (2022) -
The need for sustainable funding for Indigenous doula services in Canada
por: Wodtke, Larissa, et al.
Publicado: (2022) -
Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada
por: Verma, S., et al.
Publicado: (2007)